Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) comprise a new class of antidiabetic agents that inhibit glucose reabsorption in the renal proximal tubules. Although a recent report demonstrated the potential ability of SGLT2-Is to attenuate cancer growth of SGLT2-expressing cancer cells, little is known about the effects of SGLT2-Is on hepatocellular carcinoma (HCC). Here, we investigate the anti-cancer properties of a SGLT2-I, canagliflozin, against human liver cancer cells. SGTL2 mRNA and protein expression were detected in Huh7 and HepG2 cells, although not in HLE as well as primary human hepatocytes and hepatic stellate cells. Canagliflozin exerted antiproliferative effects on SGLT2-expressing Huh7 and HepG2 cells in a dose-dependent manner by inhibiting glycolytic metabolism including glucose uptake, lactate and intracellular ATP production. This agent also induced G2/M arrest and apoptosis with inhibited phosphorylation of ERK, p38 and AKT and cleavage of caspase3. Xenograft tumor growth assay showed that oral administration of canagliflozin (10 mg/kg/day) significantly reduced subcutaneous tumor burdens in a glycemic status-independent manner, and attenuated intratumor vascularization in Huh7-and HepG2-derived xenograft tumors in BALB/c nude mice. In vitro, canagliflozin suppressed the increased human umbilical vein endothelial cell (HUVEC) proliferation and tubular formation which were observed in Huh7 or HepG2 co-cultures. By contrast, canagliflozin had no effect on tumor growth and intratumor angiogenesis in SGLT2-null HLE-derived xenograft models. These results indicate that SGLT2-I therapy is a potential new strategy for the treatment of HCC.
Introduction
Hepatocellular carcinoma (HCC) is the sixth-most common cancer worldwide, and the second leading cause of cancerrelated mortality. 1 The notable characteristics of HCC, including a high recurrence rate and hypervascularity, have presented no satisfactory improvements in prognosis, regardless of disease etiology. Most importantly, HCC commonly develops in patients with chronic liver disease (e.g., liver cirrhosis), which worsens the prognosis. Currently, sorafenib is the standard therapeutic agent used for advanced-stage HCC, although other receptor tyrosine kinase inhibitors are likely to be implemented. 2, 3 However, cirrhotic patients often experience severe side effects, including anorexia, gastrointestinal symptoms and hand-foot syndrome, during long-term sorafenib therapy as a result of hypoactive drug metabolism. 4, 5 Consequently, an alternative approach might require the identification of a clinically available compound with antitumor activity and proven safety during long-term administration. Recent evidence has highlighted the inhibitory effects of several antidiabetic agents on HCC. For instance, an epidemiologic analysis revealed an association between metformin, a first-line medication for the treatment of type 2 diabetes (T2DM), and a reduced risk of HCC development. 6 Basic studies revealed that metformin inhibited HCC cell proliferation, invasion and angiogenesis and induced both apoptosis and autophagy through AMP-activated protein kinase (AMPK) -dependent and -independent pathways. 7, 8 In addition, dipeptidyl peptidase 4 inhibitors (DPP4-Is), which have been developed as a viable option for T2DM therapy, can enhance tumor immunity by stabilizing biologically active forms of C-X-C motif chemokine 10 and may thus yield potential therapeutic benefits for cancer patients. 9 Our recent study also revealed that DPP4-I exerted preventive effects against murine hepatocarcinogenesis via antiangiogenic and antioxidative activities. 10 Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2-Is), which comprise a new class of oral medications indicated for T2DM, can reduce glucose reabsorption in the renal proximal tubule with resultant glucosuria, without disrupting renal function. 11, 12 Consequently, SGLT2-Is can reduce plasma glucose levels and thus reverse the glucotoxicity resulting from insulin resistance. SGLTs belong to the solute carrier 5 A gene family and harness the sodium ion gradient across the plasma membrane to drive glucose and other nutrients into cells. The most well-studied family members are SGLT1 and SGLT2, which facilitate glucose transport in the kidneys and intestine, as well as in specialized regions of the brain. [11] [12] [13] [14] However, recent critical evidence has demonstrated the expression of SGLT2 in pancreatic and prostate cancer tissues, and well as the functional activity of this protein as a glucose transporter in cancer cells. 15 Furthermore, SGLT2-Is may directly suppress pancreatic cancer growth, potentially by blocking glucose uptake. 15 Recent animal study has also shown that SGLT2-I, tofogliflozin, suppresses liver tumorigenesis via reduced glucose and free fatty acid in obese and diabetic mice. 16 However, little has been reported on the direct antitumor effects of SGLT2-I on HCCs with the linkage of cancer metabolic reprograming. Here, we report the anti-cancer properties of a SGLT2-I, canagliflozin, against human liver cancer cells. We demonstrate that canagliflozin exclusively inhibits the growth of SGLT2-expressing liver cancers by reducing intracellular glucose uptake. These inhibitory effects were found to be independent of the glycemic status in murine xenograft models. Furthermore, we found that canagliflozin attenuates proangiogenic activity in SGLT2-expressing liver cancers. Based on these results, we propose that canagliflozin should be evaluated as a new treatment modality for HCC.
Material and Methods

Cell culture and reagents
The human liver cancer cell lines Huh7, HepG2 were obtained from RIKEN BRC CELL BANK (Ibaraki, Japan), and HLE and human umbilical vascular endothelial cells (HUVECs) were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan). The human normal primary hepatocyte cell line was purchased from Zenbio, Inc. (Research Triangle Park, NC). LX-2 stellate cells were kindly provided by Dr Scott Friedman (Mount Sinai School of Medicine, New York, NY). All cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Both Invitrogen, Waltham, MA) and 1% penicillin/streptomycin in an incubator at 378C, with exposure to a humidified atmosphere of 5% CO 2 . A Jurkat cell lysate was obtained from EMD Millipore (Temecula, CA). Canagliflozin was kindly provided by Mitsubishi Tanabe Pharma Co. Ltd (Osaka, Japan).
Human liver cancer xenografts
All animal procedures were performed in compliance with the recommendations of the Guide for Care and Use of Laboratory Animals (National Research Council), and the study was approved by the animal facility committee of Nara Medical University (Authorization number: 11542). Six-week-old athymic nude mice (BALB/cSlc-nu/nu) were purchased from Japan SLC, Inc. (Hamamatsu, Shizuoka, Japan). Mice were housed in stainless steel mesh cages under controlled conditions (temperature: 23 6 38C, relative humidity: 50 6 20%, 10-15 air changes/hour, illumination: 12 hr/day). The animals were allowed access to tap water ad libitum throughout the experimental period.
For tumor inoculation, 1 3 10 6 cells were suspended in 200 ll of medium and Matrigel High Concentration (Corning, Tewksbury, MA; 1:1) and subcutaneously injected into the bilateral flanks of mice. The tumor dimensions were measured with a caliper, and volumes were calculated using the following formula: 1/2 (W 2 3 L), where W and L are the measured width and length, respectively. Seven days after inoculation, the mice were orally administered canagliflozin at a dose of 100 mg/kg; mice in the vehicle group were administered an equivalent volume of saline solution. All mice were sacrificed 4 weeks after the injections, and the sizes of collected tumors were recorded. Blood and urine samples were collected from the euthanized mice after an 8-hr fast and subjected to chemical analyses. Serum biological markers and urine glucose levels were measured using routine laboratory methods.
What's new? Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) comprise a new class of antidiabetic agents that inhibit glucose reabsorption in the renal proximal tubules. Although recent evidence suggests that SGLT2-Is can attenuate growth of SGLT2-expressing cancer cells, little is known about their effects on hepatocellular carcinoma (HCC). Our study shows that the SGLT2-I canagliflozin directly inhibits the growth of SGLT2-expressing liver cancers by reducing glucose uptake and inhibiting glycolytic metabolism. Furthermore, canagliflozin attenuates proangiogenic activity in SGLT2-expressing liver cancers. Because SGLT2-Is are already used extensively without serious side effects, these agents may emerge as a new therapeutic strategy for HCC patients.
Statistical analyses
The data were subjected to Student's t-test or a one-way analysis of variance followed by Bonferroni's multiplecomparison test, where appropriate. Bartlett's test was used to determine the homology of variance. Statistical analyses were performed using Prism, version 6.04 (GraphPad Software, La Jolla, CA). All tests were two-tailed, and p-values <0.05 were considered statistically significant.
Additional methods can be found online in the Supplementary materials and methods.
Results
Canagliflozin efficiently inhibits glucose uptake and glycolytic metabolism in SGLT2-expressing human HCCs
To explore the antitumor effect of canagliflozin on human HCC cells, we initially evaluated the expression levels of SGLT2 mRNA and protein in three human HCC lines (Huh7, HepG2 and HLE) versus primary human hepatocytes (PHH) and hepatic stellate cells (LX-2). The SGLT2 mRNA levels were markedly increased in Huh7 and HepG2 cells relative to PHH and LX-2 cells; by contrast, no significant upregulation was observed in HLE cells (Fig. 1a) . Furthermore, unlike SGLT2 mRNA, the SGLT1 mRNA levels did not vary significantly among the HCC cell lines, PHH and LX-2 (Fig. 1a) . Consistent with the mRNA expression patterns, SGLT2 protein was detected in Huh7 and HepG2 cells, but not in HLE, PHH or LX-2 cells (Fig. 1b) . In accordance with previous findings, all HCC lines exhibited oncogenic overexpression of glucose transporter 1 (GLUT1), a facilitated glucose transporter (Figs. 
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We next examined the impact of canagliflozin on glucose uptake by human HCC cells. Our assays demonstrated that canagliflozin inhibited glucose transport by Huh7 and HepG2 in a dose-dependent manner (Fig. 1e ). In both cell lines, canagliflozin sufficiently inhibited glucose transport at clinically comparable doses (10 lM). Furthermore, we did not observe reduced glucose uptake by SGLT2-nonexpressing HLE cells or by PHH and LX-2 cells in response to canagliflozin, suggesting that the inhibitory effect of this drug is likely SGLT2-dependent ( Fig. 1e and Supplementary Fig. S1 ).
Glycolytic metabolism is recognized as a critical process for cancer cell viability. 18, 19 Various types of cancer cells largely produce energy via high-rate glycolysis, followed by cytosolic lactic acid fermentation rather than comparatively slower glycolysis followed by mitochondrial pyruvate oxidation, as in most normal cells. Therefore, we further investigated the lactate levels in human HCC lines. In Huh7 and HepG2, canagliflozin treatment profoundly reduced the extracellular lactate levels at 12 hr after treatment (Fig. 1f) . Previous reports of cancer metabolism have also demonstrated that ATP production must be maintained during cell growth and proliferation. 20 Strikingly, canagliflozin treatment significantly reduced the intracellular adenosine triphosphate (ATP) levels in both Huh7 and HepG2 cells (Fig. 1g ). As expected, neither the lactate nor ATP levels of HLE cells were altered by canagliflozin treatment. These findings indicate that canagliflozin interferes with glycolytic metabolism in human HCC cells in a manner dependent on SGLT2-mediated glucose uptake.
As the process of oncogenic transformation during cancer metabolic reprograming is at least partially regulated by oncogenes such as c-MYC, HRAS, SRC and HIF-1a, we also examined the mRNA expression of these genes in liver cancer lines. [21] [22] [23] [24] However, we did not observe any correlation in the expression levels of these genes with those of SGLT2 in any of the HCC cell lines ( Supplementary Fig. S2 ).
Canagliflozin suppresses human HCC cell growth by inducing cell cycle arrest and apoptosis
Given the observed inhibition of glycolytic metabolism in human HCC cells, we next assessed the effect of canagliflozin on cell growth. A cell proliferation assay revealed that canagliflozin attenuated the proliferation of Huh7 and HepG2 cells in a dose-dependent manner ( Fig. 2a) and was efficient at a clinically comparable dose (10 lM); by contrast, this drug had no effect on the proliferation of HLE cells (Fig. 2a) . In addition, we confirmed that canagliflozin did not affect the proliferative capacities of hepatic parenchymal and nonparenchymal cells that did not express SGLT2 (Supplementary Fig. S3 ).
As cancer cell growth inhibition is usually associated with cell cycle arrest, we next examined the effect of canagliflozin on the expression of cell cycle-related genes, including CDK1, CDK2, Cyclin B1, CDC25C, CHK1 and p21, in Huh7 and HepG2 cells. Our quantitative PCR results showed that canagliflozin treatment at the indicated concentration (10 lM) caused the downregulation of CDK1, CDK2, Cyclin B1 and CDC25C along with the upregulation of CHK1 and p21 in both cell lines, suggesting that canagliflozin induces G2/M arrest in human HCC cells (Fig. 2b) . Canagliflozin-treated Huh7 and HepG2 cells also exhibited a drastic increase in TdT-mediated dUTP nick end labeling (TUNEL)-positive apoptosis, compared to controls (Fig. 2c) . Consistent with changes in the proliferative capacity, cell cycle and survival status, the phosphorylation of ERK1/2, p38 and AKT was suppressed by treatment with canagliflozin in Huh7 and HepG2 cells (Fig. 2d) . Canagliflozin further enhanced the cleavage of caspase-3, in agreement with the observation of cell apoptosis induction (Fig. 2d) .
Canagliflozin reduces the human HCC xenograft tumor burden independently of glycemic status
Given the in vitro inhibitory effect of canagliflozin on human HCC cell growth, we next evaluated the effect of canagliflozin on the in vivo growth of xenograft HCC tumors in athymic nude mice. Both Huh7 and HepG2 cell-derived xenograft tumors grew progressively in the control mice, whereas the respective tumors grew slowly in mice treated with canagliflozin at a clinically comparable dose (100 mg/kg) (Figs. 3a and  3b) . At the end of experiments, the mean tumor weights were significantly lower in canagliflozin-treated mice than in control mice (Fig. 3b) . However, canagliflozin administration had no effect on the body weights of mice inoculated with human HCC cells throughout the experimental period (Fig. 3c) . As expected from the in vitro results, canagliflozin had no effect on tumor growth, tumor weight or body weight in SGLT2-null HLE-derived xenograft models (Figs. 3a-c) .
To assess whether the inhibitory effects of canagliflozin could be attributed to changes in the blood glucose levels, we next measured the glycemic statuses of xenograft model mice. All groups of canagliflozin-treated mice exhibited remarkably elevated urine glucose levels consistent with the pharmacological action of this drug (Fig. 3d) . Meanwhile, the serum glucose and insulin levels did not differ from those of control groups, indicating that the antitumor effects of canagliflozin are independent of its antidiabetic performance (Fig. 3e ). An additional analysis of serum data indicated that canagliflozin did not induce hepatotoxicity in all mice. Accordingly, canagliflozin may be a safe and effective liver cancer therapeutic agent, at least in xenograft tumor models (Fig. 3e) .
To elucidate whether SGLT2 directly affects the antitumor effects of canagliflozin, we further evaluated SGLT2 expression in the xenograft tumors. SGLT2 immunohistochemistry clearly revealed cytoplasmic staining in Huh7-and HepG2-derived xenograft subcutaneous tumors, whereas no evidence of SGLT2 expression was observed in HLE-derived tumors (Fig.  4a ). This coincided with the pronounced upregulation of SGLT2 gene and protein expression as determined respectively by quantitative PCR and western blotting of tumor tissues (Fig.  4b) . We also quantitatively assessed intratumoral cell viability via immunohistochemistry and showed that canagliflozin treatment potently abrogated Ki67-positive cell proliferation in Huh7-and HepG2-derived tumors while simultaneously inducing TUNEL-positive cell apoptosis (Fig. 4c) . Concomitant with these cell death-related features, the expression p21 and cleaved caspase3, key regulators of cell cycle and apoptosis, was notably upregulated in the subcutaneous tumors of canagliflozin-treated mice (Fig. 4d) . By contrast, HLE-derived tumors exhibited no signs of altered cell survival, in accordance with the in vitro results (data not shown). These findings suggest that the ability of canagliflozin to inhibit in vivo tumor growth is strongly associated with SGLT2 expression. 
Canagliflozin attenuates the proangiogenic activities of human HCC cells
Considerable evidence indicates a strong interaction between glucose transporter expression and angiogenesis in cancers. 25, 26 Therefore, we evaluated tumor angiogenesis in our xenograft models. A quantitative analysis of CD34-positive microvessels showed that neovascularization in both Huh7-and HepG2-derived tumors was attenuated by treatment with canagliflozin (Fig. 5a ). As expected, HLE-derived tumor angiogenesis did not differ between the control and canagliflozin-treated groups ( Supplementary Fig. S4a ).
The attenuated neovascularization in SGLT2-expressing HCCs led us to further explore the functional mechanism of canagliflozin-mediated antiangiogenic activity. First, HUVECs monocultures were grown with and without canagliflozin to evaluate the direct effect of this drug on vascular endothelial cell biology. A cell proliferation assay revealed that canagliflozin did not affect the proliferation of monocultured HUVECs (Fig. 5b) . Next, a co-culture assay was performed to investigate whether canagliflozin would induce changes in the proangiogenic activities of human HCC cells. Interestingly, co-culture with either Huh7 or HepG2 cells significantly promoted HUVEC proliferation, whereas this effect was remarkably suppressed by treatment with canagliflozin (Fig. 5b) .
We also evaluated the effect of canagliflozin on endothelial tube formation. Under normal conditions, canagliflozin failed to directly affect endothelial tube formation (Fig. 5c) . Meanwhile, Huh7-or HepG2-cultured conditional media had different effects on endothelial tube formation that depended on the presence of canagliflozin; in other words, conditional media from HCC cells cultured without canagliflozin enhanced endothelial tube formation, whereas conditional media containing canagliflozin strongly attenuated tube formation (Fig. 5c) .
These antiangiogenic effects of canagliflozin led us to profile the differential production of angiogenesis-related cytokines and chemokines in treated human HCC cells. A protein array revealed elevated interleulin-8 (IL-8) production in Huh7-cultured media and increased angiogenin (ANG) and tissue inhibitors of metalloproteinase-1 (TIMP-1) production in HepG2-cultured media (Fig. 5d) . Notably, the augmented production of cytokines and chemokines was diminished by treatment with canagliflozin, as demonstrated by significant decreases in ELISA-determined protein levels (Fig. 5e) . We further confirmed that canagliflozin reduced the levels of IL-8 and ANG and TIMP-1 mRNA in Huh7 and HepG2 cells, respectively. We did not observe significant changes in other candidate genes associated with angiogenesis ( Supplementary Fig. S4b ).
Discussion
Generally, cancer metabolic reprograming is characterized by an increased rate of glycolysis. During normal intracellular energy production, mitochondrial oxidative phosphorylation plays a predominant role under aerobic conditions, whereas glycolysis is favored and relatively little pyruvate is dispatched to the oxygen-consuming mitochondria under anaerobic conditions. In cancer cells, however, tumor hypoxia is partially associated with a metabolic shift from oxidative phosphorylation to glycolysis. 18, 19, 27 However, Warburg proposed that cancer cells can reprogram their glucose metabolism by relying on glycolysis even in the presence of oxygen. 28, 29 This "Warburg effect" confers a pronounced growth advantage to many types of cancer cells in both oxygen-rich and -poor conditions. The high rate of glycolysis in cancer cells is principally related to increased cellular glucose uptake. 18, 19, [27] [28] [29] The uptake of most hexoses into cells is facilitated by transmembrane transporters; accordingly, the increased glucose transport into cancer cells has been attributed to the upregulation of GLUT1. 17, [30] [31] [32] [33] Increasing numbers of studies have demonstrated high levels of GLUT1 expression in several cancers, including esophageal, colon, thyroid, head and neck, breast and liver cancers. 17, [30] [31] [32] [33] Furthermore, HCC tissues and cell lines reportedly express higher levels of GLUT1 mRNA, compared to primary human hepatocytes and matched nontumor tissues. 17 A comprehensive gene analysis of 152 HCC cases revealed strong correlations of increased Glut1 expression with a higher Ki67 labeling index, advanced tumor stage and poor differentiation. 17 Moreover, a genetic knockdown of GLUT1 significantly impaired the proliferative and migratory potential of HCC cells by reducing both glucose uptake and lactate secretion. 17 However, GLUT1-targeting therapies for HCC are not yet available in clinical practice.
In our study, we focused on SGLT2 as a novel antitumor agent that could target glucose uptake regulation. Under euglycemic conditions, most filtered glucose (90%) undergoes reabsorption via SGLT2 in the proximal convoluted tubule of the kidney and consequently is not excreted into the urine. 11, 12 Accordingly, SGLT2-Is, which target this process, offer unique benefits as blood glucose-lowering agents and are currently under development as adjuncts to standard care for patients with T2DM. Although normally, SGLT2 is predominantly localized in the kidney, recent studies have revealed SGLT2 expression in certain types of cancer cells; furthermore, inhibition of this transporter can suppress cancer growth. 15, 34 Regarding liver cancers, in our study we observed SGLT2 upregulation in human liver cancer cells relative to PHH and hepatic stellate cells, and found that canagliflozin-mediated SGLT2 inhibition suppressed intracellular glucose uptake in a dose-dependent manner. These findings indicate that in liver cancer cells, glucose uptake is potentially shared by SGLT2 and GLUT1.
Intriguingly, our gene expression analysis revealed heterogeneity in the oncogenic upregulation of SGLT2 among human liver cancer lines; specifically, Huh7 and HepG2 cells exhibited increased expression of SGLT2, whereas HLE did not express this transporter. Furthermore, SGLT2 upregulation distinctly coincided with the capacity of canagliflozin to inhibit glycolytic metabolism (including glucose uptake, lactate secretion, ATP production). Although the molecular regulatory mechanisms have not been fully elucidated, oncogenic signal transduction pathways appear to directly prime glycolysis. [21] [22] [23] [24] Various lines of evidence have also shown that oncogenes such as c-MYC, HRAS, SRC, HIF-1a and p53 regulate cancer metabolic reprograming and glucose transporter-encoding gene upregulation. [21] [22] [23] [24] However, we did not identify significant differences in the expression levels of these candidate oncogenes among our studied human liver cancer lines. A further comprehensive analysis of the interactions between oncogenes and SGLT2 expression in human HCC samples is needed to elucidate the molecular mechanisms underlying the observed differential SGLT2 expression pattern.
Consistent with the observation of reduced glycolysis, canagliflozin inhibited cell proliferation by inducing G2/M arrest, as indicated by the increased expression of CHK1 and p21 and decreased expression of CDK1, CDK2, Cyclin B1 and CDC25C in Huh7 and HepG2 cells. Furthermore, the inhibition of extracellular signal-regulated kinase (ERK) 1/2 and p38 phosphorylation further suggests that canagliflozin induces cell cycle arrest. These findings agree with the results from a recent basic study in which a pharmacological reduction of glucose uptake and GLUT1 downregulation induced G2/M arrest in human melanoma cells. 35 In our study, canagliflozin also facilitated apoptosis in Huh7 and HepG2 cells by activating caspase3, a central enzyme in the apoptosis pathway. Our results further revealed decreases in AKT phosphorylation in canagliflozintreated cell lines. AKT is postulated to play a key role in glycolysis regulation, as well as survival, in cancer cells. Constitutively activated AKT may stimulate glucose uptake and aerobic glycolysis in human glioblastoma cells. 36 Another report also demonstrated that the PI3K/AKT/mTOR signaling pathway not only regulates caspase3-dependent cell survival, but also stabilizes HIF-1a, a known regulator of various genes involved in glucose transport and metabolism. 37 Therefore, we consider the suppression of AKT phosphorylation to be highly relevant to canagliflozin-mediated apoptosis in liver cancer cells. A recent report discussed different mechanism by which canagliflozin could inhibit prostate and lung cancer cell growth independently of glucose uptake and AKT dephosphorylation via AMPK activation and mitochondrial respiration inhibition. 34 However, our current results showed no significant effect of canagliflozin on AMPK activation (data not shown). Collectively, our data suggest that the glucose uptake inhibition is the key mechanism that mediates HCC growth inhibition. However, Obara et al. has demonstrated that liver cancer cell growth was not directly suppressed by tofogliflozin, other kind of SGLT2-I, in contradiction to our in vitro results. 16 Their report also showed that tofogliflozin treatment did not potently affect the proliferation of liver cancer cells even under hyperglycemic and insulin resistance-mimicking conditions. These findings are of interest; the effects on liver cancer cell proliferation differ according to the type of SGLT2-I. Major explanation for this discrepancy could be difference in pharmacological activity between canagliflozin and tofogliflozin. For instance, canagliflozin possesses a low-grade inhibitory activity against SGLT1 as well as SGLT2, thus it is possible that inhibition of SGLT1 is at least partially involved in its suppressive effect on liver cancer growth.
14 Furthermore, we also suggest other important contributing factors to anticancer effect of canagliflozin. We hypothesized that canagliflozin might also affect intratumor neovascularization, as glucose metabolism is strongly associated with tumor angiogenesis. 25, 26, 38 Tumor cells secrete angiogenic activators to induce angiogenesis and thus ensure a supply of oxygen and nutrients. 39 A previous report demonstrated that pyruvate and lactate, the end-products of glycolysis, upregulate proangiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). [40] [41] [42] Therefore, we assessed changes in angiogenic activities of HCCs in response to canagliflozin as a measure of cancer microenvironmental regulation. In our study, canagliflozin attenuated the intratumoral neovascularization of xenograft HCC tumors. Furthermore, in vitro studies revealed that canagliflozin did not directly regulate the angiogenic properties of HUVECs, thus reflecting the absence of SGLT2 expression on these cells, but robustly suppressed endothelial proliferation and tubule formation by HUVECs potentiated by co-culture with Huh7 or HepG2 cells. In other words, canagliflozin indirectly suppresses tumor angiogenesis by suppressing the proangiogenic activities of HCC cells. Furthermore, we observed decreases in the production of the angiogenic inducers IL-8, angiogenin and TIMP-1 in canagliflozin-treated Huh7 and HepG2 cells. Recent evidence suggests that the NF-jB/IL-8 pathway directs lactate-driven tumor angiogenesis, thus supporting the concept that canagliflozin-mediated antiangiogenic activities rely on glycolysis inhibition. 43 Unexpectedly, our gene analysis did not reveal changes in the expression of typical angiogenic factors, such as VEGF and bFGF, following treatment with canagliflozin. Further investigation is needed to elucidate a functional mechanism that accounts for the differential effects of SGLT2 inhibition on tumor angiogenesis. We emphasize that SGLT2-Is are essentially antidiabetic agents. Diabetes is widely recognized as one of the most crucial risk factors for HCC, and various reports have provided clinical evidence supporting the preventive effects of pharmacological T2DM regulation on hepatocarcinogenesis. 44, 45 In addition to metformin and DPP4-Is, a recent animal study demonstrated that SGLT2-I suppresses diethylnitrosamineinduced hepatocarcinogenesis in diabetic mice. 16 Therefore, SGLT2-Is would be expected to exert additional effects on HCC in diabetic patients. A future investigation should determine whether the anticancer effects of canagliflozin are enhanced by hyperglycemia. However, the anticancer effect of canagliflozin is critically susceptible to the expression of SGLT2, and clinical studies will be needed to establish a strategy for identifying patients with SGLT2-positive HCCs who would benefit from SGLT2-I therapy.
In conclusion, canagliflozin appears to directly attenuate the growth of liver cancers by suppressing glycolytic metabolism and angiogenic activity. Because SGLT2-Is are already used widely in clinical practice without serious side effects, these agents may eventually emerge as a new treatment class for HCC. We believe that given our study results, epidemiological surveys of the effects of canagliflozin vs. other antidiabetic therapies on cancer incidence are warranted.
